top of page
Buscar

Arcturus expands Meiji Seika Pharma partnership with $50 million investment and new mRNA licence

Foto do escritor: nuaxia
nuaxia
há 1 dia
2 min de leitura

Meiji Seika Pharma has committed $50 million to Arcturus Therapeutics and expanded their mRNA technology partnership through a new licence, strengthening collaboration on RNA medicines and potential pandemic preparedness.


Arcturus Therapeutics announced on 16 November 2026 that Meiji Seika Pharma had agreed to invest $50 million through the purchase of approximately 2.47 million shares at $20.27 each, representing an approximately 80% premium to the relevant historical share-price average and around 7.9% of Arcturus' outstanding shares following the transaction.


The expanded relationship includes an exclusive licence covering an application of ARCT-154 technology in an undisclosed therapeutic area and a separate memorandum of understanding concerning potential pandemic preparedness collaboration in Japan, while the investment is intended to support ARCT-2601 development for ornithine transcarbamylase deficiency and validation of the LUNAR 2.0 mRNA platform.

Field

Content

Company Receiving Investment

Arcturus Therapeutics

Investment Partner

Meiji Seika Pharma

Announcement Date

16 November 2026

Transaction Type

Equity investment and expanded technology licensing collaboration

Equity Investment

$50 million

Share Purchase

Approximately 2.47 million shares

Price Per Share

$20.27

Share Price Premium

Approximately 80% to the relevant historical share-price average

Post-Transaction Ownership

Approximately 7.9% of outstanding shares

Additional Agreement

Exclusive licence for an application of ARCT-154 technology

Licensed Therapeutic Area

Undisclosed

Pandemic Preparedness Arrangement

Separate memorandum of understanding concerning potential collaboration in Japan

Development Programme Supported

ARCT-2601 for ornithine transcarbamylase deficiency

Technology Platform Supported

LUNAR 2.0 mRNA platform

Strategic Focus

RNA medicines development and expanded Japan-linked collaboration

Agreement Clarification

The pandemic preparedness memorandum is not itself a definitive licensing agreement

Primary Source

https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-50-million-investment-meiji


Discover how nuaxia can support your next medical education initiative:

 
 
 

Comentários

Avaliado com 0 de 5 estrelas.
Ainda sem avaliações

Adicione uma avaliação
bottom of page